To say that SGLT-2 inhibitor dapagliflozin has made great strides in cardiovascular care is an understatement.

Data has supported the drug’s ability to provide glycemic benefit among patients with diabetes, and recent trials have only bolstered its promise in improving cardiometabolic, cardiovascular, and renal outcome

HCP Live talked to Dr. Mikhail Kosiborod, director of Cardiometabolic Research at Saint Luke's Mid America Heart Institute and vice president of research at Saint Luke's Health System, about the clinical impact of the DAPA-HF trial. 

Read the full HCP Live article: The Significance of DAPA-HF for Cardiovascular Care and Beyond

Read more >

Related Content

Person, Hair, Nurse, Face, Female, Word
Nicole's story

"What we do is so vital. We have so much power as nurses." Nicole Roberson, Registered Nurse, Neuroscience ICU, Saint Luke's Hospital of Kansas City

Read more >
Person, Doctor, Clothing, Apparel, Lab Coat, Coat, Face, Nurse
Deb's story

Deb Day, Registered Nurse · Anderson County Hospital "I am a Saint Luke's Nurse.  Nurses are the lifeblood of Saint Luke’s compassionate care, and the life-changing work they do is...

Read more >
Apparel, Clothing, Coat, Lab Coat, Person, Doctor
Danielle's story

"You get those rare moments that you're reminded why you went into this field, and it makes everything so much better." Danielle Hammontree, Certified Family Nurse Practitioner, Saint Luke’s East Hospital

Read more >